Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 8/20 | 0.47 |
| ▸ | CTSS | P25774 | 4/20 | 0.47 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.42 |
| ▸ | CTSK | P43235 | 3/20 | 0.42 |
| ▸ | CNR2 | P34972 | 4/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | CTSV | O60911 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.37 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.37 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7467469 | 0.89 | CTSL (0.47) | CTSLCTSSCTSBCTSKCNR2 | |
| SCHEMBL6620163 | 0.85 | HSPA5 (0.49) | CTSLCTSSCTSBPRMT5WDR77 | |
| SCHEMBL7473368 | 0.84 | CTSK (0.52) | CTSLCTSSCTSBCTSK | |
| SCHEMBL6929841 | 0.84 | REN (0.45) | CTSLCTSSCTSBCTSK | |
| SCHEMBL6623377 | 0.83 | CTSL (0.47) | CTSLCTSSCTSBPRMT5WDR77 | |
| Trifluoroacetic Acid SCHEMBL7611852 | 0.79 | CTSL (0.45) | CTSLCTSSCTSBPRMT5WDR77 | |
| SCHEMBL7473976 | 0.79 | CTSL (0.49) | CTSLCTSSCTSBCTSKCNR2 | |
| SCHEMBL6927425 | 0.79 | CTSL (0.55) | CTSLCTSSCTSBCTSKCNR2 | |
| SCHEMBL7467318 | 0.79 | CTSL (0.53) | CTSLCTSSCTSBCTSKCNR2 | |
| SCHEMBL7463889 | 0.78 | CTSL (0.49) | CTSLCTSSCTSBCTSKCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0983228-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | disclosed |
| US-20020065230-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-05-30 | — | — | US | disclosed |
| EP-0983228-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998050342-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065230-A1 | Protease inhibitors | PRSS1, DNPEP, CTSZ | CTSL 4/4885CTSS 10/4885CTSB 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.